Clinical trials: Healthy Volunteers, Aged
Influenza
Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
The objectives of this Phase I/II study are to assess the safety and immunogenicity of two different dose levels of a non-adjuvanted H5N1 influenza vaccine in a healthy young adult population.
- Trial name
- NCT00517517
- Testing
- Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation
- Where
- 4 sites in Hong Kong, Singapore
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Healthy Volunteers
Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female Subjects
The purpose of this study is to evaluate the safety and tolerability of 3 different dose levels of ASP3772 administered subcutaneously or intramuscularly to Japanese healthy adults 20 to 49 years of age.
- Trial name
- NCT04265911
- Testing
- ASP3772 (subcutaneous), ASP3772 (intramuscular), PPSV23 (subcutaneous)
- Where
- Japan
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Affinivax, Inc.
Healthy
Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China
In the study Influvac will be compared to Agrippal, another subunit influenza vaccine that is already on the market in China. The main objective of the study is to show that both vaccines are comparable with regard to efficacy.
- Trial name
- NCT00325260
- Testing
- Influvac; subunit influenza vaccine
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Heart Failure
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Kidney Disease and in Age-, Weight- and Gender-matched Healthy Participants
Vericiguat (BAY1021189) is under development to treat heart failure, a condition in in which the heart has trouble pumping blood through the body.
- Trial name
- NCT04722484
- Testing
- Vericiguat (BAY1021189)
- Where
- Germany
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bayer
Meningococcal Disease
Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea
A multicenter, single arm, post-marketing surveillance study. This study is a postlicensure requirement of the Korea Food and Drug Administration (KFDA) to provide continued safety evaluation of MenACWY in the Korean population…
- Trial name
- NCT01766206
- Testing
- MenACWY-CRM (Menveo)
- Where
- 54 sites in South Korea
- Volunteers
- 3,948 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster
Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older
The purpose of this study is to evaluate the persistence of immune response to the HZ vaccine as well as safety up to 10 years after the first dose of initial vaccination course.
- Trial name
- NCT02735915
- Testing
- Herpes Zoster Vaccine GSK1437173A
- Where
- 7 sites in Czechia, Germany and 1 more
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dementia With Lewy Bodies, Alzheimer's Disease
A Trial of 18F-AV-133 and 18F-AV-45 Positron Emission Tomography (PET)
The purpose of this study is to evaluate the ability to identify individuals with dopaminergic degeneration in group of patients with a clinical diagnosis of either dementia with Lewy bodies (DLB) or idiopathic Parkinson's…
- Conditions
- Dementia With Lewy Bodies, Alzheimer's Disease, Parkinson's Disease
- Trial name
- NCT01503944
- Testing
- 18F-AV-133, 18F-AV-45
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Diabetes, Healthy
Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers
This trial is conducted in Europe. The aim of this trial is to compare the exposure of liraglutide in young versus elderly healthy subjects.
- Trial name
- NCT01507337
- Testing
- liraglutide
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy
A Study of the Safety of PAZ-417 in Healthy Elderly Adults
This is study to determine the safety of PAZ-417 in healthy adults over 65.
- Trial name
- NCT00663065
- Testing
- PAZ-417
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia, Alzheimer Disease
Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers
Single site, parallel-group, double-blind trial of low or high dose of BI 409306 to evaluate the ocular and systemic safety and pharmacokinetics during 14 day treatment period in patients with schizophrenia, Alzheimer's disease…
- Trial name
- NCT02392468
- Testing
- BI 409306 25 mg, BI 409306 50 mg
- Where
- 3 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteers
A Double-blind, Placebo-controlled Study to Evaluate Very Low Dose LSD in Healthy Volunteers Aged 55-75 Years
This study was a Phase 1, double-blind, placebo-controlled, randomised study of very low dose LSD. Healthy volunteers aged 55 to 75 years with no use of LSD in the past 5 years were screened within 28 days of randomization.
- Trial name
- NCT04421105
- Testing
- Lysergic acid diethylamide (LSD) 5µg, Lysergic acid diethylamide (LSD) 10µg, Lysergic acid diethylamide (LSD)20 µg
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Eleusis Therapeutics
Worsening Chronic Heart Failure, Diabetic Nephropathy
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
Researchers are looking for a better way to treat people who have worsening of chronic heart failure, a long-term condition where the heart does not pump blood as well as it should, as well as to treat patients who have diabetic…
- Trial name
- NCT04881994
- Testing
- Finerenone (BAY94-8862)
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bayer
Hepatic Impairment, Healthy
An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment
To evaluate and compare the pharmacokinetics and safety of ONO-2745/CNS 7056 in subjects with the hepatic impairment and matched healthy subjects.
- Trial name
- NCT01790607
- Testing
- ONO-2745 /CNS 7056
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Ono Pharma USA Inc
Stargardt Disease, Age-related Macular Degeneration
Phase 1 Safety Study of ALK-001 in Healthy Volunteers
This protocol is a phase 1 clinical study to assess the safety and pharmacokinetics of ALK-001 in healthy volunteers. Please contact trials@alkeus.com for any questions.
- Conditions
- Stargardt Disease, Age-related Macular Degeneration, Other Retinal Dystrophies
- Trial name
- NCT02230228
- Testing
- ALK-001 (No generic name)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Alkeus Pharmaceuticals, Inc.
Dengue
Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults
The main purpose of this study is to assess the immunogenicity and safety of the concomitant and sequential administration of yellow fever (YF) vaccine and tetravalent dengue vaccine (TDV) in healthy participants aged 18 to 60…
- Trial name
- NCT03342898
- Testing
- YF-17D, TDV
- Where
- 11 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Takeda
Rabies (Healthy Volunteers)
Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen
To demonstrate the immunogenicity of Sinovac rabies vaccine is non-inferior to the active-controlled rabies vaccine (Verorab®) after post-exposure prophylaxis (PEP) vaccination, and to confirm its satisfying safety profile in the…
- Trial name
- NCT07055893
- Testing
- Rabies vaccine, Verorab®
- Where
- Pakistan
- Volunteers
- 390 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Infections, Bacterial
Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects
This study will be conducted in three parts (Part 1, Part 2 and Part 3). Part 1 of this study will evaluate the relative bioavailability of a single dose of GSK2140944 tablet formulation compared to the reference capsule…
- Trial name
- NCT02045849
- Testing
- GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending oral doses of ASP6282 in healthy male and female subjects.
- Trial name
- NCT02420782
- Testing
- ASP6282, Itraconazole, Pilocarpine
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Herpes Zoster
Safety and Immunogenicity of SYS6017 in Healthy Participants Aged 40 Years or More
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT06954818
- Testing
- A zoster mRNA vaccine SYS6017
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Hepatitis E
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)
This phase IV clinical study was designed to evaluate the safety and immunogenicity of the recombinant Hepatitis E vaccine(Hecolin®), manufactured by Xiamen Innovax Biotech CO., LTD., in healthy volunteers aged over 65 years of…
- Trial name
- NCT02417597
- Testing
- Recombinant Hepatitis E Vaccine (Escherichia Coli)
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd